Basel, Switzerland – 29 April, 2024, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective immediately. Alberto joined Alentis in 2021 as Head of Oncology.
”It is becoming increasingly clear that targeting Claudin-1 has tremendous potential for treating cancer. As CSO, it is my objective to harness the full potential of Claudin-1 with the development of anti-Claudin-1 ADCs to benefit a wide range of cancer patients.
Alberto TosoChief Scientific Officer, Alentis Therapeutics
About Alentis:
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering anti-CLDN1 antibodies and ADCs to modify and reverse the course of disease.
Learn more here.
